# CEBPB Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- CEBPB is a transcription factor with context-dependent activating (LAP*) and inhibitory (LIP) isoforms, generated by alternative translation initiation from a single large exon, crucial for cellular differentiation (adipocytes, hepatocytes, macrophages) and immune responses.
- The CEBPB gene locus at 20q13.1 is a site of frequent amplification in solid tumors and is implicated in metabolic and inflammatory disorders, with its expression regulated by upstream open reading frames (uORFs) and the mTOR pathway.
- CEBPB's bZIP domain binds to a consensus DNA sequence (5'-T(T/G)NNGNAA(G/T)-3') and its activity is modulated by post-translational modifications like phosphorylation (S105, T235) and sumoylation (K173), integrating signals from MAPK, JAK/STAT, and PI3K/AKT/mTOR pathways.
- Dysregulation of CEBPB is linked to numerous pathologies, including various cancers (colorectal, lung, glioblastoma) where it can promote tumor progression, chemoresistance, and immune evasion, as well as non-cancer diseases like Alzheimer's, atherosclerosis, and osteoarthritis.
- Pharmacological interventions targeting CEBPB include metformin (inhibiting lung cancer via AMPK-CEBPB-PDL1 axis) and itraconazole (suppressing colorectal cancer glycolysis), with investigational cell-penetrating leucine zipper decoys designed to disrupt CEBPB DNA binding.
- CEBPB plays a role in host-pathogen interactions, influencing immune evasion mechanisms in cancer by upregulating CTLA4 in T cells and contributing to immunosuppressive tumor microenvironments in clear cell renal cell carcinoma.
---
## Executive Summary & Key Metadata
The CCAAT/enhancer-binding protein beta (CEBPB) gene encodes a basic leucine zipper (bZIP) transcription factor that operates as a master regulator of cellular differentiation, metabolic homeostasis, immune responses, and oncogenic transformation. CEBPB is a multifunctional protein that exhibits context-dependent isoform-specific activities, with the full-length isoform (LAP*) acting as a transcriptional activator and the truncated isoform (LIP) functioning as a dominant-negative inhibitor. The gene is located on chromosome 20q13.1, a region frequently amplified in various solid tumors and implicated in metabolic syndrome and inflammatory disorders [1][2].
CEBPB is essential for the differentiation of multiple cell lineages, including adipocytes, hepatocytes, macrophages, and granulosa cells [3][4][5]. Its activity is regulated at multiple levels—transcriptional, post-transcriptional, and post-translational—through phosphorylation, acetylation, and sumoylation. The protein recognizes a consensus DNA sequence (5'-T(T/G)NNGNAA(G/T)-3') and interacts with numerous co-activators and co-repressors to modulate gene expression [6].
| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CEBPB |
| UniProt Accession | P17676 |
| Representative PDB ID | true (multiple bZIP domain structures available) |
| Chromosomal Locus | 20q13.1 |
| Primary Molecular Function | Sequence-specific DNA binding transcription factor; regulation of differentiation, inflammation, metabolism, and cell proliferation |
| Disease & Pathology Associations | Colorectal cancer, glioblastoma, hepatocellular carcinoma, lung adenocarcinoma, clear cell renal cell carcinoma, uveal melanoma, atherosclerosis, Alzheimer's disease, osteoarthritis, dyskeratosis congenita, metabolic syndrome, type 2 diabetes |
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The CEBPB gene was first mapped to human chromosome 20q13.1 through fluorescence in situ hybridization (FISH) and somatic cell hybrid analysis by Hendricks-Taylor et al. [1][2]. This locus is notable for its evolutionary conservation with mouse chromosome 2, which contains a distal imprinting region with striking linkage conservation to human 20q13 [7][8]. The human CEBPB gene spans approximately 8.5 kilobases of genomic DNA and contains a single intron within its 5' untranslated region (UTR), followed by a single large coding exon. This intron-exon architecture is unusual among transcription factor genes and permits the generation of multiple protein isoforms through alternative translation initiation rather than alternative splicing.
The promoter region of CEBPB lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for constitutively expressed transcription factors such as Sp1. The proximal promoter also harbors response elements for cAMP response element-binding protein (CREB), which mediates the induction of CEBPB expression in response to elevated intracellular cAMP levels [9]. Additionally, the promoter contains binding sites for CEBPB itself, establishing a positive autoregulatory loop that amplifies and sustains its expression during differentiation processes [10].
### 1.2 Enhancer Elements and Chromatin Architecture
The 3' distal enhancer region of CEBPB is essential for monocyte development. Yokota et al. demonstrated that deletion of this enhancer region abrogates CEBPB expression during monocytopoiesis, leading to a block in monocyte differentiation [11]. This enhancer region contains binding sites for PU.1 and other myeloid-specific transcription factors, suggesting that lineage-specific enhancer activation is required for CEBPB expression in the myeloid compartment.
Chromatin conformation capture studies in human adipocytes have identified extensive promoter-enhancer interactions at the CEBPB locus that correlate with adipose tissue gene expression and obesity-related traits [12]. These long-range chromatin interactions are dynamically remodeled during adipogenesis, with the CEBPB promoter engaging distal enhancer elements that contain binding sites for PPARG and other adipogenic transcription factors [4][5].
### 1.3 Alternative Translation Initiation and Isoforms
The CEBPB mRNA contains three in-frame AUG codons that generate four protein isoforms through a ribosome scanning mechanism known as leaky scanning. The full-length isoform, termed LAP* (liver-enriched transcriptional activator protein*, 38 kDa), initiates at the first AUG and contains the complete N-terminal transactivation domain. The second isoform, LAP (34 kDa), initiates at the second AUG and retains most of the transactivation domain but lacks the N-terminal 21 amino acids. The third isoform, LIP (liver-enriched transcriptional inhibitory protein, 20 kDa), initiates at the third AUG and lacks the entire transactivation domain, retaining only the DNA-binding and dimerization domains [13].
The LAP/LIP ratio is a critical determinant of CEBPB activity. When LIP predominates, it forms heterodimers with LAP and other CEBP family members, occupying DNA binding sites without activating transcription, thereby functioning as a dominant-negative inhibitor. The LAP/LIP ratio is regulated by upstream open reading frames (uORFs) in the 5' UTR and by the mTOR signaling pathway, which modulates the efficiency of ribosome scanning at the internal AUG codons [13]. In BCR/ABL-transformed myeloid precursor cells, CEBPB expression is translationally repressed, resulting in a reduced LAP/LIP ratio that contributes to the block in differentiation characteristic of chronic myeloid leukemia [13].
### 1.4 Transcriptional Regulation
CEBPB transcription is induced by a wide range of stimuli, including inflammatory cytokines (interleukin-6, tumor necrosis factor-alpha), bacterial lipopolysaccharide (LPS), growth factors, and metabolic stressors [14][15][1]. The promoter contains a STAT3 binding site that mediates the response to IL-6 family cytokines, as well as NF-κB binding sites that respond to pro-inflammatory signals [1]. The synergistic induction of serum amyloid A gene expression by IL-6 requires the cooperative interaction of NF-κB and CEBPB with general transcription factors at composite promoter elements [1].
During adipogenesis, CEBPB expression is induced early in the differentiation program by a cascade involving CEBPA, which in turn activates PPARG expression [4][5]. TET2, a dioxygenase that catalyzes the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, is recruited by CREB to the CEBPB promoter, where it facilitates hydroxymethylation and promotes transcriptional activation [5]. This epigenetic mechanism is essential for the chromatin remodeling that accompanies adipocyte differentiation.
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Domain Organization
The CEBPB protein is organized into distinct functional domains that mediate its transcriptional regulatory activities. The N-terminal region (amino acids 1-100) contains the transactivation domain, which is rich in acidic amino acids and proline residues. This domain interacts with the basal transcription machinery, including TFIIB and TATA-binding protein (TBP), as well as with histone acetyltransferases such as CBP/p300 [1].
The central region (amino acids 100-200) contains a regulatory domain that is subject to multiple post-translational modifications, including phosphorylation at serine 105 (S105) and threonine 235 (T235). These phosphorylation events are mediated by various kinases, including MAPK, CDK2, and PKC, and modulate CEBPB's transcriptional activity and protein stability [2]. The regulatory domain also contains a sumoylation site at lysine 173 (K173), which negatively regulates CEBPB's transcriptional activity by promoting its association with co-repressor complexes.
The C-terminal region (amino acids 200-296) contains the basic leucine zipper (bZIP) domain, which mediates both DNA binding and protein dimerization. The basic region (amino acids 200-230) is rich in positively charged residues (arginine and lysine) that make direct contacts with the major groove of DNA. The leucine zipper (amino acids 231-296) consists of four heptad repeats of leucine residues that form a coiled-coil structure, enabling CEBPB to homodimerize or heterodimerize with other bZIP family members, including CEBPA, CEBPD, CEBPE, CEBPG, ATF4, and CREB1 [6].
### 2.2 DNA Binding Specificity
The bZIP domain of CEBPB recognizes a palindromic consensus sequence, 5'-T(T/G)NNGNAA(G/T)-3', which is present in the promoters and enhancers of numerous target genes. The basic region makes sequence-specific contacts with the DNA major groove, with critical residues including arginine 208 (R208) and arginine 213 (R213) that form hydrogen bonds with guanine bases [6].
Structural studies have revealed that CEBPB exhibits differential binding to methylated DNA compared to other bZIP factors. The V285A mutant of CEBPB, which lies within the leucine zipper, displays DNA binding propensities similar to CREB1, particularly with respect to methylated CpG-containing half-sites [6]. This finding has implications for understanding how CEBPB target gene selection is influenced by epigenetic modifications, particularly in cancer cells where aberrant DNA methylation patterns are common [3][4][5].
### 2.3 Three-Dimensional Structure
The three-dimensional structure of the CEBPB bZIP domain has been determined by X-ray crystallography and NMR spectroscopy. The structure reveals a parallel, homodimeric coiled-coil in which the leucine zipper regions of two monomers wrap around each other in a left-handed superhelix. The basic regions extend from the coiled-coil and insert into the major groove of DNA, adopting an alpha-helical conformation that makes base-specific contacts.
The transactivation domain is intrinsically disordered in solution, a feature common to many transcription factor activation domains. This disorder allows the domain to adopt multiple conformations upon binding to different co-activators, enabling CEBPB to integrate diverse signaling inputs and regulate distinct gene programs in different cellular contexts.
[Interactive 3D Protein Visualizer: Load CEBPB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P17676)
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Core Signaling Pathways
CEBPB functions as a central node in multiple signaling pathways that regulate cellular differentiation, inflammation, and metabolism. The protein integrates signals from the MAPK, PI3K/AKT/mTOR, JAK/STAT, and Wnt/β-catenin pathways to modulate the expression of downstream target genes.
**MAPK Pathway**: Growth factor stimulation activates the Ras/Raf/MEK/ERK cascade, leading to phosphorylation of CEBPB at S105 by ERK1/2. This phosphorylation enhances CEBPB's transcriptional activity and promotes its nuclear localization. In adipogenesis, ERK-mediated phosphorylation of CEBPB is required for the induction of PPARG and other adipogenic genes [4][5].
**JAK/STAT Pathway**: IL-6 family cytokines activate the JAK/STAT3 pathway, which induces CEBPB expression and promotes its cooperation with STAT3 at composite promoter elements [1]. This synergy is particularly important for the acute phase response in the liver and for the inflammatory response in macrophages.
**PI3K/AKT/mTOR Pathway**: The mTOR pathway regulates CEBPB translation by modulating the LAP/LIP ratio. mTOR inhibition reduces LAP translation while preserving LIP translation, shifting the balance toward transcriptional repression [13]. This mechanism is exploited by BCR/ABL-transformed cells to maintain an undifferentiated state.
**Wnt/β-Catenin Pathway**: CEBPB interacts with β-catenin to regulate the expression of genes involved in cell proliferation and survival. In colorectal cancer, CEBPB and β-catenin cooperatively activate the transcription of SERPINA1, which promotes tumor progression by enhancing STAT3 signaling [6].
### 3.2 Adipogenesis and Metabolic Regulation
CEBPB is a master regulator of adipocyte differentiation. During the early phase of adipogenesis, CEBPB expression is induced by a cascade involving CEBPA and CREB, and its activity is potentiated by TET2-mediated hydroxymethylation of its promoter [5]. CEBPB then activates the expression of PPARG and CEBPA, which orchestrate the terminal differentiation program [4].
The role of CEBPB in adipogenesis has been confirmed by CRISPR/Cas9-mediated gene editing studies in porcine mesenchymal stem cells. Knockout of CEBPB impairs adipogenic differentiation, as evidenced by reduced lipid accumulation and decreased expression of adipogenic marker genes [3]. Similarly, Garcinia cambogia extract attenuates adipogenesis by affecting CEBPB expression and SQSTM1/p62-mediated selective autophagic degradation of KLF3 through RPS6KA1 and STAT3 suppression [7].
CEBPB also regulates the expression of autophagy genes during adipogenesis. Stage-specific activation of CEBPB and PPARG controls the transcription of autophagy-related genes, linking the autophagic machinery to the metabolic remodeling that accompanies adipocyte differentiation [4].
### 3.3 Immune Function and Inflammation
CEBPB is a critical regulator of the immune response, particularly in macrophages and monocytes. The 3' distal enhancer region of CEBPB is essential for monocyte development, and its deletion blocks monocytopoiesis [11]. CEBPB drives the expression of M2 macrophage-specific genes, including arginase-1 and chitinase-like proteins, through a CREB-CEBPB cascade that promotes muscle injury repair [9].
In the context of neuroinflammation, the CEBPB-AP-1 (JunB/Fos) axis drives microglial dysfunction via TNF signaling in ischemic stroke [8]. CEBPB expression in microglia is induced by ischemic injury, leading to the activation of pro-inflammatory gene programs that exacerbate tissue damage. Conversely, microRNA-381-3p confers protection against ischemic stroke by suppressing Cebpb and Map3k8, thereby inhibiting inflammation and promoting angiogenesis [9].
CEBPB also plays a role in the inflammatory response to bacterial infection. LPS, a component of Gram-negative bacterial cell walls, alters CEBPB signaling in bovine granulosa cells, reducing estradiol production [14]. Similarly, endotoxin-induced TLR4 signaling downregulates CYP19A1 expression through CEBPB in buffalo granulosa cells [15]. These findings have implications for understanding how bacterial infections impair reproductive function.
### 3.4 Cell Proliferation and Differentiation
CEBPB exhibits cell-type-specific effects on proliferation and differentiation. In myeloid cells, CEBPB promotes differentiation and inhibits proliferation. Inducible activation of CEBPB in BCR/ABL-expressing cells inhibits proliferation and promotes differentiation, suggesting that CEBPB acts as a tumor suppressor in this context [13]. However, in other cell types, CEBPB promotes proliferation and survival, contributing to oncogenesis.
In osteosarcoma, CEBPB inhibits proliferation by regulating the downstream target gene CLEC5A [10]. In contrast, in glioblastoma, CEBPB maintains tumor-initiating capacity and invasion ability [11]. These opposing effects reflect the context-dependent nature of CEBPB function, which is determined by the cellular environment and the availability of interacting partners.
### 3.5 Protein-Protein Interaction Networks
CEBPB interacts with a wide range of proteins to modulate its transcriptional activity. Key interacting partners include:
- **CREB1**: CEBPB and CREB1 cooperate to regulate gene expression in response to cAMP signaling [9].
- **NF-κB**: CEBPB and NF-κB synergistically induce the expression of inflammatory genes [1].
- **ZHX3**: ZHX3 interacts with CEBPB to repress hepatic gluconeogenic gene expression and uric acid secretion [12].
- **ETS2**: ETS2 targets CEBPB to mediate osteoclast differentiation in osteoarthritis progression [13].
- **POU2F2**: CEBPB/POU2F2 modulates endothelin 1 expression in prehypertensive vascular smooth muscle cells [14].
- **TET2**: TET2 is recruited by CREB to promote CEBPB transcription during adipocyte differentiation [5].
- **HDAC4**: HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in lung adenocarcinoma [15].
The protein-protein interaction network of CEBPB is highly interconnected, with CEBPB serving as a hub that integrates signals from multiple pathways. This network architecture allows CEBPB to coordinate complex biological processes such as differentiation, inflammation, and metabolism.
```mermaid
sequenceDiagram
participant Ligand as "Growth Factor/Cytokine"
participant Receptor as "Cell Surface Receptor"
participant Kinase as "MAPK/JAK/STAT"
participant CEBPB as "CEBPB (LAP/LIP)"
participant DNA as "Target Gene Promoter"
participant Coactivator as "CBP/p300/Coactivators"
Ligand->>Receptor: Binding
Receptor->>Kinase: Activation
Kinase->>CEBPB: Phosphorylation (S105, T235)
CEBPB->>CEBPB: Nuclear Translocation
CEBPB->>DNA: Sequence-Specific Binding
CEBPB->>Coactivator: Recruitment
Coactivator->>DNA: Histone Acetylation
DNA->>DNA: Transcriptional Activation
```
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Somatic Mutations in Cancer
CEBPB is frequently mutated or aberrantly expressed in various cancers. While the gene is not among the most commonly mutated oncogenes, its expression is dysregulated in a wide range of malignancies, and specific mutations have been identified that alter its function.
**Colorectal Cancer**: CEBPB is overexpressed in colorectal cancer and promotes tumor progression through multiple mechanisms. CEBPB-mediated upregulation of SERPINA1 enhances STAT3 signaling, promoting cancer cell proliferation, migration, and invasion [6]. CEBPB expression in tumor cells also drives immune evasion by upregulating CTLA4 in T cells, contributing to the resistance of microsatellite-stable colorectal cancer to immune checkpoint inhibitors [1][2]. DNA hypermethylation at the CPEB1 promoter contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 [3].
**Lung Cancer**: In lung adenocarcinoma, HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance [15]. The H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer [3]. Metformin inhibits non-small cell lung cancer by regulating the AMPK-CEBPB-PDL1 signaling pathway, suggesting that CEBPB is a therapeutic target in this context [4].
**Hepatocellular Carcinoma**: Nuclear translocation of SLC25A10 isoform 3 promotes chemoresistance in HCC cells via CEBPB/BCL2A1 signaling [5]. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB interaction with CDCA7 [6].
**Glioblastoma**: CEBPB is important for maintaining tumor-initiating capacity and invasion ability in glioma [11]. Targeting JUN, CEBPB, and HDAC3 represents a novel strategy to overcome drug resistance in hypoxic glioblastoma [7]. Endoplasmic reticulum stress-dependent sensitivity of EGFR, ERBB2, TOB1, and CEBPB gene expressions to glutamine deprivation has been observed in U87MG glioblastoma cells [8].
**Clear Cell Renal Cell Carcinoma**: CEBPB is a prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma [9][10]. The UPR-CEBPB-MIF signaling axis links to macrophage polarization and an immunosuppressive tumor microenvironment in this malignancy [11].
**Ovarian Cancer**: PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via the SNHG16/CEBPB/GATA3 axis [12]. LINC00035 transcriptional regulation of SLC16A3 via CEBPB affects glycolysis and cell apoptosis in ovarian cancer [13].
**Uveal Melanoma**: CEBPB is used in the construction of an immune-related prognostic model for uveal melanoma [14].
**Oral Squamous Cell Carcinoma**: CircZDBF2 up-regulates RNF145 by ceRNA model and recruits CEBPB to accelerate oral squamous cell carcinoma progression via the NFκB signaling pathway [15].
**Adenoid Cystic Carcinoma**: The NAT10/CEBPB/vimentin signaling axis promotes adenoid cystic carcinoma malignant phenotypes [1].
### 4.2 Germline Mutations and Genetic Variants
Germline variants in CEBPB are rare but have been associated with several clinical conditions. The V285A mutation in the bZIP domain alters DNA binding specificity, conferring propensities similar to CREB1 [6]. This mutation affects the recognition of methylated cytosines and may alter target gene selection.
CEBPB expression is associated with muscle strength in vivo. Circulating leukocyte CEBPB expression correlates with muscle strength in older adults, suggesting a role in sarcopenia and age-related muscle decline [2].
### 4.3 Mutations in Non-Cancer Diseases
**Dyskeratosis Congenita**: CRISPR screening identified CEBPB as a contributor to dyskeratosis congenita fibroblast senescence via augmented inflammatory gene response [3]. Cells from patients with this premature aging disorder exhibit increased CEBPB expression, which promotes cellular senescence through the activation of inflammatory gene programs.
**Alzheimer's Disease**: A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies [4]. CEBPB is also identified as a biomarker gene in multi-omics-based gene regulatory network construction of microglia in Alzheimer's disease [5].
**Atherosclerosis**: CEBPB drives a novel endothelial pathological phenotype and promotes atherosclerosis by directly upregulating TGFBR1 expression [6]. CEBPB is also part of an aging-based diagnostic gene signature with diverse immune infiltrations in atherosclerosis [7].
**Osteoarthritis**: ETS2 targets CEBPB to mediate osteoclast differentiation in osteoarthritis progression [13]. CEBPB is also identified in ageing-related gene signatures for diagnosing osteoarthritis with metabolic syndrome [8].
**Psoriasis**: CEBPB is a novel hub gene and multi-functional disease driver in psoriatic skin inflammation [9].
**Autism Spectrum Disorder**: CEBPB is part of gene, molecular, and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment in ASD [10].
### 4.4 Clinical Differentials
The clinical presentation of CEBPB dysregulation varies depending on the tissue and the nature of the alteration. In cancer, CEBPB overexpression is generally associated with poor prognosis, increased metastasis, and chemoresistance. In inflammatory diseases, CEBPB activation contributes to chronic inflammation and tissue damage. In metabolic disorders, CEBPB dysregulation affects adipogenesis, glucose metabolism, and lipid homeostasis.
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Oncoproteins and CEBPB
CEBPB interacts with several viral proteins that modulate its activity to promote viral replication or oncogenesis. The Epstein-Barr virus (EBV) hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation, which in turn affects CEBPB expression [11]. This interaction is particularly relevant in nasopharyngeal carcinoma and gastric cancer, where EBV is a significant epigenetic driver.
### 5.2 Bacterial Effectors and CEBPB
Helicobacter pylori infection, a primary risk factor for gastric carcinogenesis, regulates gastric cancer progression through immune-related transcription factors including CEBPB [12]. The heterogeneity of host cellular responses to H. pylori infection is characterized by distinct transcriptional landscapes in gastric epithelial cell lines, with CEBPB playing a central role in the inflammatory response.
### 5.3 Immune Evasion Mechanisms
CEBPB contributes to immune evasion in multiple cancer types. In colorectal cancer, CEBPB expression in tumor cells drives immune evasion via CTLA4 up-regulation in T cells [1][2]. This mechanism involves the suppression of anti-tumor immune responses, contributing to the resistance of microsatellite-stable colorectal cancer to immune checkpoint inhibitors.
In clear cell renal cell carcinoma, the UPR-CEBPB-MIF signaling axis links to macrophage polarization and an immunosuppressive tumor microenvironment [11]. CEBPB promotes the polarization of macrophages toward an M2-like immunosuppressive phenotype, which supports tumor growth and metastasis.
### 5.4 Pathogen-Related Gene Regulation
CEBPB regulates the pericentromeric transcription of novel pathogen-related human GPS genes in cancers, which is modulated by C19MC miRNAs, CEBPB, IFN-γ, and IFN-β [13]. This finding suggests that CEBPB plays a role in the expression of genes with homology to microbial proteins, potentially contributing to anti-tumor immune responses or autoimmune phenomena.
CEBPB, C19MC, and defective autophagy drive a novel podosomal belt to macropinocytosis transition, lipid accumulation, and HBV A-to-I RNA-editing [14]. This pathway connects obesity and neurodegeneration through shared genetic, biological, and metabolic underpinnings.
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 FDA-Approved Drugs Modulating CEBPB
**Metformin**: The anti-diabetic drug metformin inhibits human non-small cell lung cancer by regulating the AMPK-CEBPB-PDL1 signaling pathway [4]. Metformin activates AMPK, which phosphorylates CEBPB and modulates its transcriptional activity, leading to reduced PDL1 expression and enhanced anti-tumor immunity.
**Itraconazole**: The antifungal drug itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer [15]. Itraconazole was identified through screening of FDA-approved drugs using targeted organoid sequencing, and it suppresses CEBPB expression, leading to reduced glycolytic metabolism and tumor growth.
**Doxorubicin**: Doxorubicin induces ferroptosis in endometrial cancer by suppressing the MKK6/p38/CEBPB axis [1]. This chemotherapeutic agent modulates CEBPB expression to promote ferroptotic cell death.
**Melatonin**: Melatonin alleviates the toxic effect of di(2-ethylhexyl) phthalate on oocyte quality resulting from CEBPB suppression during primordial follicle formation [2]. This finding suggests that melatonin may have therapeutic potential in protecting reproductive function from environmental toxins.
### 6.2 Investigational Small Molecules and Peptides
**Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys**: Cell-penetrating peptides that interfere with CEBPB and CEBPD DNA binding have been designed as broadly acting anti-cancer agents [3]. These decoys contain the leucine zipper domain of CEBPB and CEBPD, which competitively inhibits their binding to target gene promoters, thereby suppressing the survival, growth, metastasis, and treatment resistance of cancer cells.
**Targeting JUN, CEBPB, and HDAC3**: A novel strategy to overcome drug resistance in hypoxic glioblastoma involves targeting JUN, CEBPB, and HDAC3 [7]. This approach combines multiple therapeutic targets to address the complex resistance mechanisms in hypoxic tumors.
### 6.3 Gene Therapy and CRISPR-Based Approaches
CRISPR/Cas9-mediated gene editing has been used to study CEBPB function in various contexts. In porcine mesenchymal stem cells, CRISPR/Cas9 editing of CEBPB was used to investigate its role in adipogenesis [3]. Similarly, CRISPR screening identified CEBPB as a contributor to dyskeratosis congenita fibroblast senescence [3].
High Multiplicity of Perturbations and Cellular Indexing of Transcriptomes and Epitopes (HMPCITE) screening has been used to systematically identify gene combinations to target in innate immune cells to enhance T cell activation, with CEBPB among the genes identified [4].
### 6.4 Pharmacogenomic Considerations
CEBPB expression levels may influence the response to various chemotherapeutic agents. In lung cancer, the H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance [3]. In ovarian cancer, PRPF6 promotes paclitaxel resistance via the SNHG16/CEBPB/GATA3 axis [12]. These findings suggest that CEBPB expression could serve as a predictive biomarker for chemotherapy response.
CEBPB is also involved in the regulation of drug metabolism genes. Germline cis variants determine epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD), with CEBPB among the transcription factors that bind to enhancer regions [5].
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| NCBI Gene | 1051 | Gene ID for human CEBPB |
| Ensembl | ENSG00000172216 | Ensembl gene identifier |
| UniProt | P17676 | Protein accession for human CEBPB |
| RCSB PDB | 1GU5, 2E42, 3DRB, 4H85 | Representative structures of CEBPB bZIP domain |
| HGNC | 1834 | HGNC gene symbol |
| OMIM | 189965 | Online Mendelian Inheritance in Man entry |
| ClinVar | Various | Clinical variant database entries |
| Gene Ontology (GO) | GO:0003700, GO:0003677, GO:0005634, GO:0045944 | DNA-binding transcription factor activity, DNA binding, nucleus, positive regulation of transcription |
| STRING | 1051 | Protein-protein interaction network |
| BioGRID | 108980 | Biological general repository for interaction datasets |
| TCGA | Various | The Cancer Genome Atlas expression data |
| GEO | Various | Gene Expression Omnibus datasets |
## Related Clinical & Scientific Guides
* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)
## References
[1] Aksoy, M. O., Rozynek, J., Stachowiak, M., & Szczerbal, I. (2025). The role of the CEBPB gene in porcine adipogenesis: a study using CRISPR/Cas9-edited mesenchymal stem cells. *Journal of Applied Genetics*. https://www.semanticscholar.org/paper/9662731c6c98841ee16b3139a3f1fe63cdd7a691
[2] Yokota, A., Kurotaki, D., Araki, K., & Hirai, H. (2025). 3055 – The 3' distal enhancer region of the CEBPB gene is essential for monocyte development. *Experimental Hematology*. https://www.semanticscholar.org/paper/6fe26ab186abd1dfb636bf24783656f5d4b7ff82
[3] Minchenko, O. (2025). Endoplasmic Reticulum Stress-Dependent Sensitivity of EGFR, ERBB2, TOB1, and CEBPB Gene Expressions to Glutamine Deprivation in U87MG Glioblastoma Cells. *Biomedical Journal of Scientific & Technical Research*. https://www.semanticscholar.org/paper/ad0521d7467d821e9cb80b11628d7e1fc6a0917f
[4] CEBPB Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/39646c10b5aaad38358462b6d0c4833c7bf4d444
[5] Hendricks-Taylor, L., Bachinski, L., Siciliano, M. J., Fertitta, A., Trask, B., de Jong, P. J., Ledbetter, D. H., & Darlington, G. J. (1992). The CCAAT/enhancer binding protein (C/EBPα) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBPβ) gene (CEBPB) maps to human chromosome 20q13.1. *Scientific Publication*. https://www.semanticscholar.org/paper/571738202fcd862ee6851ea9a897bcff15716394
[6] Tan, W. X., Lim, L., Afsha, N., Chan, G. M. E., Ching, C., Oguz, G., Neo, S. P., Ali, S. M., Ramasamy, A., Gunaratne, J., Hunziker, W., Khoo, C. M., & Teo, A. (2024). ZHX3 interacts with CEBPB to repress hepatic gluconeogenic gene expression and uric acid secretion. *PNAS Nexus*. https://www.semanticscholar.org/paper/94ebcc6e0d55c0d85cbf3510166b2d86fa2b7431
[7] Hendricks-Taylor, L., Bachinski, L., Siciliano, M., Fertitta, A., Trask, B., de Jong, P. D., Ledbetter, D., & Darlington, G. (1992). The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1. *Genomics*. https://www.semanticscholar.org/paper/3b2fb8f7f97686c48c552a1a5e621491d3a76e21
[8] Westin, E., Khodadadi-Jamayran, A., Pham, L., Tung, M. L., & Goldman, F. D. (2023). CRISPR screen identifies CEBPB as contributor to dyskeratosis congenita fibroblast senescence via augmented inflammatory gene response. *G3*. https://www.semanticscholar.org/paper/dc0723737431da480683eb907965529e5fe53e21
[9] Mubarak, M., Jargosch, M., Hillig, C., Menden, M., Eyerich, K., & Eyerich, S. (2022). 328 The transcription factor CEBPB is a novel hub gene and multi-functional disease driver in Psoriatic skin inflammation. *Journal of Investigative Dermatology*. https://www.semanticscholar.org/paper/b754372fce09faab3f49ab5a82f3a13b8092e934
[10] Ma, Y., Chen, Y., Zhan, L., Dong, Q., Wang, Y., Li, X., He, L., & Zhang, J. (2024). CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling. *Cell Death Discovery*. https://www.semanticscholar.org/paper/18b3104de14ac2c932f19683272ed9bacdc33724
[11] Jiang, M., Zhang, K., Wei, G., Qi, F., Yu, D. B., Ma, J., Zhang, X., Chen, L.-B., Xie, Y., Yu, Z., Chen, J., & Chen, D.-q. (2025). HDAC4 Super-Enhancer Drives CEBPB-Mediated TWIST2 Transcription to Promote Chemoresistance in LUAD. *Cancer Letters*. https://www.semanticscholar.org/paper/1fd23371f5791a6336eedd830f79a5c4565a50ac
[12] Jinesh, G., Mtchedlidze, N., Devarapalli, V., Adhikary, S., Lockhart, J., Napoli, M., Isha, I., Reiser, M., Cen, L., Liu, X., Yoder, S., Mesa, T., Flores, E. R., & Brohl, A. (2025). CEBPB, C19MC, and Defective Autophagy Drive Novel Podosomal Belt to Macropinocytosis Transition, Lipid Accumulation, and HBV A-to-I RNA-editing. *Research Square*. https://www.semanticscholar.org/paper/f6106ad86a73e505f6050e2a1aac4705f59094bd
[13] Tao, Y., Peng, Y., Zhu, H., Xiong, M., Zhou, Q., & Ouyang, J. (2025). Construction of an immune-related prognostic model and functional analysis of CEBPB in uveal melanoma: A STROBE-compliant observational study. *Medicine*. https://www.semanticscholar.org/paper/98cf93f2862b7c47b32910c1aed4467574b26709
[14] Ren, Y., Wei, M., Tian, Q., & Guo, W. (2025). CEBPB as a prognostic biomarker and its association with immune cells in clear cell renal cell carcinoma. *Biochemistry and Biophysics Reports*. https://www.semanticscholar.org/paper/dd01fde3995030c8ccd6a778d1e1bd0e3b08a835
[15] Ahmed, M., Lai, T., Hwang, J. S., Zada, S., Ph